Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: goldsachstrader who wrote (8394)	12/2/2009 1:38:38 AM
From: kdd999	Respond to of 63325

It's a hematology meeting. No one giving presentations would be qualified to answer such questions. Save em for the IMMU annual meeting.

To: goldsachstrader who wrote (8394)	12/2/2009 4:58:13 PM
From: tbone0096	Read Replies (2) \| Respond to of 63325

will look forward to hearing what responses you got to those questions - hope you were able to get some of those questions asked, although i suspect you wouldn't get very good answers to #'s 2, 3 and 4, and probably 5. for #6 i would think they would decline comment as negotiations are ongoing, and for #1 the obvious answer is that they were hoping that favorable developments would lead to a better price to do a secondary, but hindsight is 20/20 and that obviously has yet to develop. we can always hope that a strong update at ASCO-GI could change that in a significant way, although there are those that will still fight to push it back down, knowing that developments in this company, and biotech in general, are slow to happen and they have time on their side (that could always change with the right partnership or development, at least i will keep hoping that's the case :-)